Info

Theregen, Inc. is a cell therapy company that develops cell-based therapies for patients with cardiovascular disease. Theregen has worldwide exclusive rights to research, manufacture, develop and commercialize its lead product, Anginera,, for cardiovascular and vascular applications. The company is conducting two Phase I human clinical safety trials for Anginera, a cell-based epicardial therapy. Anginera has been shown in animal models to have the potential to induce remodeling and angiogenesis in the ischemic heart, leading to functional changes that may benefit patients with heart failure. The company's early-stage financial strategy calls for partnerships with institutional and corporate investors to fund clinical development and provide the resources to research additional product candidates. The company has received equity investments from Sanderling Ventures and Boston Scientific Corporation to help fund clinical development of Anginera. Sanderling continues in 2007 to provide funding necessary to advance the company's clinical programs. Theregen's platform technology also provides attractive product development partnering opportunities. Research into exciting new technologies such as gene therapy and targeted drug delivery has run into serious obstacles. Biotechnology and pharmaceutical companies have begun to recognize the need for living, cell-based, three-dimensional constructs, such as Anginera, as a means of overcoming these barriers and bringing these technologies to fruition.